; or (v) a direct-to-consumer in vitro clinical test. (c) Public meeting and input (1) Public docket Not later than 30 days after the date of enactment of the Verifying Accurate Leading-edge IVCT Development Act of 2020 , the Secretary shall establish a public docket to receive comments concerning recommendations for implementation of this section, including criteria and procedures for subsections (e) through (j). The public docket shall remain open for the duration of time that this section remains in effect. (2) Public meeting Not later than 180 days after the date of enactment of the Verifying Accurate Leading-edge IVCT Development Act of 2020 , the Secretary shall convene a public meeting to which stakeholders from organizations representing patients and consumers, academia, and the in vitro clinical test industry are invited in order to discuss components of the technology certification process including application requirements, inspections, alignment with third-party accreditors, and the definition of technology under section 587(17). The public meeting shall be assigned a docket number by the Commissioner of Food and Drugs and made available for the submission of public comments. (d) Guidance In accordance with section 5 of the Verifying Accurate Leading-edge IVCT Development Act of 2020 , the Secretary shall issue a draft guidance on technology review including describing criteria or procedures relating to technology review under this section, which shall be subject to public comment for a minimum of 60 days from issuance prior to finalizing such guidance documents after considering the comments received. The guidance shall include an outline of the application and recertification process, opportunities to meet with officials of the Food and Drug Administration, plans to streamline inspections, and a list of applicable technologies. The guidance shall be updated as appropriate, and not less frequently than each time the Secretary identifies a unique technology. (e) Application for technology